Article | Published:

Rational design of syn-safencin, a novel linear antimicrobial peptide derived from the circular bacteriocin safencin AS-48

The Journal of Antibioticsvolume 71pages592600 (2018) | Download Citation

Abstract

Bacteriocins hold unprecedented promise as a largely untapped source of antibiotic alternatives in the age of multidrug resistance. Here, we describe the first approach to systematically design variants of a novel AS-48 bacteriocin homologue, which we have termed safencin AS-48, from Bacillus safensis, to gain insights into engineering improved activity of bacteriocins. A library of synthetic peptides in which systematic amino acid substitutions to vary the periodicity and abundance of polar, acidic, aliphatic, and hydrophobic residues were generated for a total of 96 novel peptide variants of a single bacteriocin candidate. Using this method, we identified nine synthetic safencin (syn-safencin) variants with broad and potent antimicrobial activities with minimal inhibitory concentrations (MIC) as low as 250 nM against E. coli, P. aeruginosa, X. axonopodis, and S. pyogenes with minimal cytotoxicity to mammalian cells. It is anticipated that the strategies we have developed will serve as general guides for tuning the specificity of a given natural bacteriocin compound for therapeutic specificity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    CDC. Antibiotic resistance threats in the United States. United States Department of Health and Human Services, Centers for Disease Control and Prevention. 2013 (http://www.cdc.gov/drugresistance/threat-report-2013/).

  2. 2.

    Ageitos JM, Sánchez-Pérez A, Calo-Mata P, Villa TG. Antimicrobial peptides (AMPs): ancient compounds that represent novel weapons in the fight against bacteria. Biochem Pharmacol. 2017;133:117–38.

  3. 3.

    Uggerhøj LE, et al. Rational design of alpha-helical antimicrobial peptides: do’s and don’ts. ChemBioChem. 2015;16:242–53.

  4. 4.

    Fjell CD, Hiss JA, Hancock REW, Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov. 2012;11:37–51.

  5. 5.

    Lv Y, et al. Antimicrobial properties and membrane-active mechanism of a potential α-helical antimicrobial derived from cathelicidin PMAP-36. PLoS ONE. 2014;9:e86364.

  6. 6.

    Ong ZY, Wiradharma N, Yang YY. Strategies employed in the design and optimization of synthetic antimicrobial peptide amphiphiles with enhanced therapeutic potentials. Adv Drug Deliv Rev. 2014;78:28–45.

  7. 7.

    Alvarez-Sieiro P, Montalbán-López M, Mu D, Kuipers OP. Bacteriocins of lactic acid bacteria: extending the family. Appl Microbiol Biotechnol. 2016;100:2939–51.

  8. 8.

    Cotter PD, Ross RP, Hill C. Bacteriocins—a viable alternative to antibiotics? Nat Rev Microbiol. 2013;11:95–105.

  9. 9.

    Arnison PG, et al. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep. 2013;30:108–60.

  10. 10.

    Field D, et al. A bioengineered nisin derivative to control biofilms of Staphylococcus pseudintermedius. PLoS ONE. 2015;10:e0119684.

  11. 11.

    Field D, Cotter PD, Hill C, Ross RP. Bioengineering lantibiotics for therapeutic success. Front Microbiol. 2015;6:1–6.

  12. 12.

    Murinda SE, Rashid KA, Roberts RF. In vitro assessment of the cytotoxicity of nisin, pediocin, and selected colicins on simian virus 40-transfected human colon and Vero monkey kidney cells with trypan blue staining viability assays. J Food Prot. 2003;66:847–53.

  13. 13.

    Field D, Cotter PD, Ross RP, Hill C. Bioengineering of the model lantibiotic nisin. Bioengineered. 2015;5979:37–41.

  14. 14.

    Lamarche MJ, et al. Discovery of LFF571: an investigational agent for Clostridium difficile infection. J Med Chem. 2012;55:2376–87.

  15. 15.

    Mullane K, et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015;59:1435–40.

  16. 16.

    Burgos MJG, Aguayo MCL, Pulido RP, Gálvez A, López RL. Inactivation of Staphylococcus aureus in oat and soya drinks by enterocin AS-48 in combination with other antimicrobials. J Food Sci. 2015;80:2030–4.

  17. 17.

    Caballero Gómez N, Abriouel H, José Grande M, Pérez Pulido R, Gálvez A. Combined treatments of enterocin AS-48 with biocides to improve the inactivation of methicillin-sensitive and methicillin-resistant Staphylococcus aureus planktonic and sessile cells. Int J Food Microbiol. 2013;163:96–100.

  18. 18.

    Gómez NC, Abriouel H, Grande J, Pulido RP, Gálvez A. Effect of enterocin AS-48 in combination with biocides on planktonic and sessile Listeria monocytogenes. Food Microbiol. 2012;30:51–8.

  19. 19.

    Sánchez-Hidalgo M, et al. AS-48 bacteriocin: close to perfection. Cell Mol Life Sci. 2011;68:2845–57.

  20. 20.

    Montalbán-López M, Martínez-Bueno M, Valdivia E, Maqueda M. Expression of linear permutated variants from circular enterocin AS-48. Biochimie. 2011;93:549–55.

  21. 21.

    Angeles Jiménez M, Barrachi-Saccilotto AC, Valdivia E, Maqueda M, Rico M. Design, NMR characterization and activity of a 21-residue peptide fragment of bacteriocin AS-48 containing its putative membrane interacting region. J Pept Sci. 2005;11:29–36.

  22. 22.

    Montalbán-López M, et al. Characterization of linear forms of the circular enterocin AS-48 obtained by limited proteolysis. FEBS Lett. 2008;582:3237–42.

  23. 23.

    Thévenet P, et al. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 2012;40:W288–93.

  24. 24.

    Maupetit J, Derreumaux P, Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res. 2009;37:W498–503.

  25. 25.

    Fimland G, Eijsink VGH, Nissen-Meyer J. Mutational analysis of the role of tryptophan residues in an antimicrobial peptide. Biochemistry. 2002;41:9508–15.

  26. 26.

    Nguyen, LT, et al. Serum stabilities of short tryptophan-and arginine-rich antimicrobial peptide analogs. PLoS ONE. 2010;5:1–8.

  27. 27.

    Aurell CA, Wistrom AO. Critical aggregation concentrations of gram-negative bacterial lipopolysaccharides (LPS). Biochem Biophys Res Commun. 1998;253:119–23.

  28. 28.

    Avitabile C, D’Andrea LD, Romanelli A. Circular dichroism studies on the interactions of antimicrobial peptides with bacterial cells. Sci Rep. 2014;4:4293.

  29. 29.

    Sreerama N, Woody RW. Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal Biochem. 2000;287:252–60.

  30. 30.

    Yadavalli SS, et al. Antimicrobial peptides trigger a division block in Escherichia coli through stimulation of a signalling system. Nat Commun. 2016;7:12340.

  31. 31.

    Deslouches B, et al. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob Agents Chemother. 2013;57:2511–21.

  32. 32.

    Mikut R, et al. Improving short antimicrobial peptides despite elusive rules for activity. BBA Biomembr. 2016;1858:1024–33.

  33. 33.

    Mojsoska B, Carretero G, Larsen S, Mateiu RV, Jenssen H. Peptoids successfully inhibit the growth of gram negative E. coli causing substantial membrane damage. Sci Rep. 2017;7:42332.

  34. 34.

    Cebrián R, et al. The bacteriocin AS-48 requires dimer dissociation followed by hydrophobic interactions with the membrane for antibacterial activity. J Struct Biol. 2015;190:162–72.

Download references

Author information

Affiliations

  1. Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, 46556, USA

    • Francisco R. Fields
    • , Katelyn E. Carothers
    •  & Shaun W. Lee
  2. Eck Institute for Global Health, Notre Dame, IN, 46556, USA

    • Francisco R. Fields
    • , Katelyn E. Carothers
    •  & Shaun W. Lee
  3. Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA

    • Rashna D. Balsara
    • , Victoria A. Ploplis
    •  & Francis J. Castellino
  4. W.M Keck Center for Transgene Research, Notre Dame, IN, 46556, USA

    • Rashna D. Balsara
    • , Victoria A. Ploplis
    •  & Francis J. Castellino
  5. Chemistry-Biochemistry-Biology Interface Program, Notre Dame, IN, 46556, USA

    • Shaun W. Lee

Authors

  1. Search for Francisco R. Fields in:

  2. Search for Katelyn E. Carothers in:

  3. Search for Rashna D. Balsara in:

  4. Search for Victoria A. Ploplis in:

  5. Search for Francis J. Castellino in:

  6. Search for Shaun W. Lee in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding authors

Correspondence to Francisco R. Fields or Shaun W. Lee.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41429-018-0032-4